Wu C H, Pan J S, Chang W C, Hung J S, Mao Simon J T
Department of Pharmacology, School of Medicine, China Medical University, 91 Hsueh-Shieh Road, Taichung, 404, Taiwan.
J Biomed Sci. 2005;12(3):503-12. doi: 10.1007/s11373-005-6900-5.
The pathological mechanism of restenosis is primarily attributed to excessive proliferation of vascular smooth muscle cells (SMC). Actinomycin D has been regarded as a potential candidate to prevent balloon injury-induced neointimal formation. To explore its molecular mechanism in regulating cell proliferation, we first showed that actinomycin D markedly reduced the SMC proliferation via the inhibition of BrdU incorporation at 80 nM. This was further supported by the G1-phase arrest using a flowcytometric analysis. Actinomycin D was extremely potent with an inhibitory concentration IC50 at 0.4 nM, whereas the lethal dose LD50 was at 260 microM. In an in vivo study, the pluronic gel containing 80 nM and 80 microM actinomycin D was applied topically to surround the rat carotid adventitia; the thickness of neointima was substantially reduced (45 and 55%, respectively). The protein expression levels of proliferating cell nuclear antigen (PCNA), focal adhesion kinase (FAK), and Raf were all suppressed by actinomycin D. Extracellular signal-regulated kinases (Erk) involved in cell-cycle arrest were found to increase by actinomycin D. These observations provide a detailed mechanism of actinomycin D in preventing cell proliferation thus as a potential intervention for restenosis.
再狭窄的病理机制主要归因于血管平滑肌细胞(SMC)的过度增殖。放线菌素D被认为是预防球囊损伤诱导的新生内膜形成的潜在候选药物。为了探究其调节细胞增殖的分子机制,我们首先发现,在80 nM浓度下,放线菌素D通过抑制BrdU掺入显著降低了SMC增殖。流式细胞术分析显示细胞停滞于G1期,进一步支持了这一结果。放线菌素D的抑制作用极强,其半数抑制浓度(IC50)为0.4 nM,而致死剂量(LD50)为260 μM。在一项体内研究中,将含有80 nM和80 μM放线菌素D的普朗尼克凝胶局部应用于大鼠颈动脉外膜周围;新生内膜厚度显著降低(分别降低了45%和55%)。放线菌素D抑制了增殖细胞核抗原(PCNA)、粘着斑激酶(FAK)和Raf的蛋白表达水平。发现参与细胞周期停滞的细胞外信号调节激酶(Erk)因放线菌素D而增加。这些观察结果揭示了放线菌素D预防细胞增殖的详细机制,因此可作为再狭窄的一种潜在干预手段。